Australian Super Pty LTD Eli Lilly & CO Transaction History

Australian Super Pty LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 28, 2023	BUY	$350.74 - $468.98 $1.04 Million - $1.39 Million	2,968 New	2,968 $1.39 Million
Q4 2021 Jan 24, 2022	SELL	$224.85 - $279.04 $94.5 Million - $117 Million	-420,295 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$221.6 - $272.71 $16.9 Million - $20.8 Million	-76,351 Reduced 15.37%	420,295 $97.1 Million
Q2 2021 Aug 12, 2021	BUY	$180.55 - $233.54 $8.65 Million - $11.2 Million	47,898 Added 10.67%	496,646 $114 Million
Q1 2021 May 14, 2021	BUY	$164.32 - $212.72 $49.6 Million - $64.2 Million	301,700 Added 205.17%	448,748 $83.8 Million
Q4 2020 Feb 11, 2021	BUY	$130.46 - $172.63 $19.2 Million - $25.4 Million	147,048 New	147,048 $24.8 Million

4,011

751M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $756B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Australian Super Pty LTD, based on Form 13F filings with the SEC.

Stay updated on Australian Super Pty LTD with notifications on news.